Drugs Made In America Acquisition Ii Corp. (DMII) Stock Price & Analysis
Drugs Made In America Acquisition Ii Corp. (DMII) rose 0.00% to USD 10.09 as of June 11, 2026 at 07:06 UTC, according to Nexqual real-time market data.
DMII last closed at USD 10.09; the session ranged USD 10.09–10.09 on volume of 3,451 shares. Market capitalization is $642.73M, with a 52-week range of USD 9.86–10.09 (NGM). Source: Nexqual, June 11, 2026 at 07:06 UTC.
Key Statistics (as of June 11, 2026 at 07:06 UTC)
| Price | USD 10.09 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.09 |
| Open | USD 10.09 |
| Day Range | USD 10.09 – 10.09 |
| 52-Week Range | USD 9.86 – 10.09 |
| Volume | 3,451 shares |
| Market Cap | $642.73M |
| Exchange | NGM |
Technical Analysis (DMII)
Nexqual's technical model rates DMII "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 11, 2026 at 07:06 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 82.69 (overbought) |
| vs SMA50 | Above (USD 10.03) |
| MACD | 0.02 (positive) |
Analyst Ratings (DMII)
Wall Street analysts rate DMII "None", per Nexqual as of June 11, 2026 at 07:06 UTC.
| Consensus Rating | None |
|---|
Earnings (DMII)
Source: Nexqual, June 11, 2026 at 07:06 UTC.
Financials & Fundamentals (DMII)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.53 |
| Total Cash | $347,720 |
| Total Debt | $450,000 |
Source: Nexqual, June 11, 2026 at 07:06 UTC.
Financial Health Score (DMII)
Nexqual rates Drugs Made In America Acquisition Ii Corp.'s overall financial health "Weak" across five dimensions, as of June 11, 2026 at 07:06 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $348K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Mixed — No data |
Ownership (DMII)
| Insider Ownership | +15.21% |
|---|---|
| Institutional Ownership | +70.55% |
| Shares Outstanding | 63.70M |
| Float | 50.26M |
| Short % of Float | +0.11% |
Source: Nexqual, June 11, 2026 at 07:06 UTC.
Leadership (DMII)
Drugs Made In America Acquisition Ii Corp. is led by Roger Bendelac (age 68), Chief Executive Officer, per Nexqual as of June 11, 2026 at 07:06 UTC.
| Chief Executive Officer | Roger Bendelac (age 68) |
|---|
Major Backers & Investors (DMII)
Notable institutional backers of Drugs Made In America Acquisition Ii Corp. include Magnetar Financial LLC, MMCAP International, Inc. SPC, Karpus Management, Inc., according to Nexqual as of June 11, 2026 at 07:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Magnetar Financial LLC | 4.24% |
| MMCAP International, Inc. SPC | 4.24% |
| Karpus Management, Inc. | 4.08% |
| Glazer Capital LLC | 3.69% |
| Healthcare of Ontario Pension Plan Trust Fund | 3.14% |
| Millennium Management | 3.1% |
| Hudson Bay Capital Management Lp | 3.09% |
| Wolverine Asset Management, LLC | 2.82% |
Source: Nexqual, June 11, 2026 at 07:06 UTC.
From Drugs Made In America Acquisition Ii Corp.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- The aim will be for this business to have end-to-end capability from plant-based raw material production for a spectrum of controlled substances (the Active Pharmaceutical Ingredients ("API")) to drug manufacturing and prescriptions filled by pharmacies or directly to the patients.   The post-business combination company would aim to grow revenues building on an addressable market for the estimated $44 billion plant-based production segment, API market, and generic medications.
- Because we are able to complete our initial business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.
Partnerships
- If any third party refuses to execute an agreement waiving such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will enter into an agreement with a third party that has not executed a waiver only if management believes that such third party's engagement would be significantly more beneficial to us than any alternative.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CEPF | Cantor Equity Partners IV, Inc. | USD 10.32 | ▲ 0% |
| EVAC | EQV Ventures Acquisition Corp. | USD 10.16 | ▼ 0.29% |
| CEPV | Cantor Equity Partners V, Inc. | USD 10.29 | ▼ 0.19% |
| KFII | K&F Growth Acquisition Corp. II | USD 10.53 | ▼ 0.09% |
| CRAQ | Cal Redwood Acquisition Corp. | USD 10.28 | ▲ 0.15% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 07:06 UTC. This page is informational and not investment advice.